Pasithea Therapeutics is a biotechnology company focused on the research and discovery of treatments for psychiatric and neurological disorders. Co.'s secondary operations focus on establishing anti-depression clinics across the U.K. and providing business support services to similar entities in the U.S., using trained pharmacists to administer intravenous infusions of ketamine. The KTTA average annual return since 2021 is shown above.
The Average Annual Return on the KTTA average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether KTTA average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KTTA average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|